Prediction of In Vivo Drug-Drug Interactions from In Vitro Data: Factors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4

HS Brown, A Galetin, D Hallifax, JB Houston - Clinical pharmacokinetics, 2006 - Springer
Background Quantitative predictions of in vivo drug-drug interactions (DDIs) resulting from
metabolic inhibition are commonly made based upon the inhibitor concentration at the …
被引用次数：155 相关文章

Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4

HS Brown, A Galetin, D Hallifax… - Clinical …, 2006 - go.gale.com
Background: Quantitative predictions of in vivo drug-drug interactions (DDIs) resulting from
metabolic inhibition are commonly made based upon the inhibitor concentration at the …

Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.

HS Brown, A Galetin, D Hallifax… - Clinical …, 2006 - europepmc.org
Background Quantitative predictions of in vivo drug-drug interactions (DDIs) resulting from
metabolic inhibition are commonly made based upon the inhibitor concentration at the …

[引用][C] Prediction of In Vivo Drug-Drug Interactions from In Vitro Data

HS Brown, A Galetin, D Hallifax, JB Houston - Clinical Pharmacokinetics, 2006 - cir.nii.ac.jp
Prediction of In Vivo Drug-Drug Interactions from In Vitro Data | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …

[引用][C] Prediction of in vivo drug-drug interactions from in vitro data: Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4

HS BROWN, A GALETIN, D HALLIFAX… - Clinical …, 2006 - pascal-francis.inist.fr
Prediction of in vivo drug-drug interactions from in vitro data : Factors affecting prototypic
drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4 CNRS Inist Pascal-Francis …

Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4

HS Brown, A Galetin, D Hallifax… - Clinical …, 2006 - pubmed.ncbi.nlm.nih.gov
Background Quantitative predictions of in vivo drug-drug interactions (DDIs) resulting from
metabolic inhibition are commonly made based upon the inhibitor concentration at the …

[引用][C] Prediction of in vivo drug-drug interactions from in vitro data: Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4

HS BROWN, A GALETIN, D HALLIFAX… - Clinical …, 2006 - Adis International